13522-86-6

Basic information

• Product Name: 2-ISOPROPYL-4-METHOXYPHENOL
• Synonyms: 2-ISOPROPYL-4-METHOXYPHENOL;PHENOL, 4-METHOXY-2-(1-METHYLETHYL)-;EOS-61048
• CAS NO: 13522-86-6
• Molecular Formula: C₁₀H₁₄O₂
• Molecular Weight: 166.22
• Mol File: 13522-86-6.mol

Chemical Properties

• Boiling Point: 263 °C at 760 mmHg
• Flash Point: 113.6 °C
• Appearance: /
• Density: 1.026 g/cm³
• PKA: 10.97±0.18(Predicted)
• CAS DataBase Reference: 2-ISOPROPYL-4-METHOXYPHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-ISOPROPYL-4-METHOXYPHENOL(13522-86-6)
• EPA Substance Registry System: 2-ISOPROPYL-4-METHOXYPHENOL(13522-86-6)

Safety Data

• Hazardous Substances Data: 13522-86-6(Hazardous Substances Data)

Usage

Uses

Used in Medical and Surgical Applications:
2-Isopropyl-4-methoxyphenol is used as a general anesthetic for the induction and maintenance of anesthesia during surgeries and medical procedures. It is favored for its rapid onset, short duration of action, and ability to provide a smooth recovery.
The use of propofol is crucial in various medical scenarios, including but not limited to:
Induction of anesthesia before surgery
Maintenance of sedation during medical procedures
Treatment of certain sleep disorders
However, its use is accompanied by potential side effects such as respiratory depression, hypotension, and pain upon injection, which must be carefully managed by medical professionals. Despite these drawbacks, propofol remains a widely used and important tool in anesthetic care due to its efficacy and versatility in clinical settings.

Upstream product

• 2349-71-5 2-isopropylhydroquinone 
• 77-78-1 dimethyl sulfate 
• 15000-00-7 2-(1-hydroxy-1-methyl-ethyl)-4-methoxy-phenol 
• 705-15-7 1-(2-hydroxy-5-methoxyphenyl)ethan-1-one 
• 676-58-4 methylmagnesium chloride 
• 6295-35-8 6-methoxy-4-methyl-chromen-2-one 
• 67-56-1 methanol 
• 88-69-7 2-(1-methylethyl)phenol 
• 124-41-4 sodium methylate 
• 187737-37-7 propene 
• 150-76-5 4-methoxy-phenol 
• 26307-50-6 4-bromo-2-isopropyl-phenol 

Downstream Products

• 927872-64-8 2-(2-isopropyl-4-methoxyphenoxy)acetonitrile 
• 865305-34-6 toluene-4-sulfonic acid 2-isopropyl-4-methoxy-phenyl ester 
• 865305-35-7 toluene-4-sulfonic acid 2-isopropyl-4-methoxy-5-nitro-phenyl ester 
• 865305-36-8 toluene-4-sulfonic acid 2-isopropyl-4-methoxy-3-nitro-phenyl ester 
• 865305-38-0 2-isopropyl-4-methoxy-3-nitro-phenol 
• 865305-37-9 2-isopropyl-4-methoxy-5-nitro-phenol 
• 114650-46-3 2-isopropyl-4-methoxyaniline 
• 865304-71-8 5-(2-isopropyl-4-methoxy-phenoxy)-pyrimidine-2,4-diamine 
• 865305-33-5 5-(5-amino-2-isopropyl-4-methoxy-phenoxy)-pyrimidine-2,4-diamine 
• 865305-41-5 5-(2-isopropyl-5-isothiocyanato-4-methoxy-phenoxy)-pyrimidine-2,4-diamine 
• 865305-40-4 4-chloro-N-[5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-phenyl]butyramide 
• 865305-39-1 (2-isopropyl-4-methoxy-5-nitro-phenoxy)-acetonitrile 

Relevant articles and documents

Development of a green and sustainable manufacturing process for gefapixant citrate (MK-7264) Part 2: Development of a robust process for phenol synthesis

Various synthetic routes to 2-isopropyl-4-methoxyphenol 3, the phenol core of Gefapixant citrate (MK-7264), are described, which provide better alternatives to the initial four-step supply route. These new routes include a coumarin fragmentation approach in flow, a rhenium-catalyzed isopropylation of mequinol, and a bromination/methoxylation of 2-isopropylphenol. After exploring several approaches, a robust two-step process for the preparation of 3 from the commodity starting material 2-isopropylphenol was developed. The optimized route employs a highly regioselective bromination. After isolating the bromophenol DABCO cocrystal, a copper-catalyzed methoxylation delivers 3 in high yield. This route is successfully demonstrated at the plant scale with low process mass intensity and cost.

NOVEL PROCESS FOR SYNTHESIS OF A PHENOXY DIAMINOPYRIMIDINE COMPOUND

Disclosed herein is a novel process for preparing Compound A free base, 5-((2,4-diaminopyrimidin-5-yl)oxy)-4-isopropyl-2-methoxybenzenesulfonamide, and a citrate salt of Compound A with simplified chemistry and a high overall yield: Compound A. In one emb

METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS

Provided herein include methods and compositions for treating diseases or conditions. In some embodiments provided are methods for treating one or more diseases or conditions selected from the group consisting of hypertension, heart failure, dyspnea, and

Direct synthesis of anilines and nitrosobenzenes from phenols

A one-pot synthesis of anilines and nitrosobenzenes from phenols has been developed using an ipso-oxidative aromatic substitution (iSOAr) process. The products are obtained in good yields under mild and metal-free conditions. The leaving group effect on reactions that proceed through mixed quionone monoketals has also been investigated and a predictive model has been established.

Methods of Using Diaminopyrimidine P2X3 and P2X 2/3 Receptor Modulators for Treatment of Acute and Sub-Acute Cough, Urge to Cough and Chronic Cough, in Respiratory Diseases

Methods for treating cough, chronic cough and urges to cough associated with respiratory diseases with a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of Formu

Ethylene glycol as hydrogen donor for the syntheses of thymol analogues via hydrolysis of 4-methylcoumarins

Treatment of 4-methylcoumarins with potassium hydroxide in ethylene glycol resulted in the formation of the 'normal' 2-isopropenylphenols and/or the 'abnormal' 2-isopropylphenols depending on the nature of the substrates. The solvent ethylene glycol was b

Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X3/P2X2/3 antagonist for the treatment of pain

The purinoceptor subtypes P2X3 and P2X2/3 have been shown to play a pivotal role in models of various pain conditions. Identification of a potent and selective dual P2X3/P2X2/3 diaminopyrimidine antagonist RO-4

Diaminopyrimidines as P2X3 and P2X2/3 modulators

Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the compounds being of formula (I): wherein R1, R2, R3 and R4 are as defined herein.

Diaminopyrimidines as P2X3 and P2X2/3 modulators

Compounds of formula (I): wherein R1 and R2 are as defined herein. Also disclosed are methods of making and using the subject compounds.